Your Source for Venture Capital and Private Equity Financings

iECURE Raises $65M Series A-1 Round

2022-11-30
PHILADELPHIA, PA, iECURE, a gene editing company, announced the completion of a $65 million Series A-1 financing.
PHILADELPHIA, PA, iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced the completion of a $65 million Series A-1 financing.

The Series A-1 financing was co-led by Novo Holdings A/S and LYFE Capital with significant participation from existing investors Versant Ventures and OrbiMed Advisors.

This financing, coupled with the $50 million raised in the prior Series A financing announced in September 2021, will bring the company's total funds raised to $115 million.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors